Latest News for: isth

Edit

Kedrion Biopharma advances rare disease scientific sessions at ISTH 2026 (Kedrion SpA)

Public Technologies 14 Jul 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 133083812) .
Edit

Kedrion Biopharma Advances Rare Disease Scientific Evidence Generation at ISTH 2026

PR Newswire 14 Jul 2026
"By investing in clinical research, collaborating with experts, and sharing new evidence at forums like ISTH, we're helping advance the understanding of rare diseases while supporting better care for patients around the world.".
Edit

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed ...

Enid News & Eagle 13 Jul 2026
WILMINGTON, Del.--(BUSINESS WIRE)--Jul 13, 2026-- ... .
Edit

ISTH 2026: Incyte Presentations and Posters (Incyte Corporation)

Public Technologies 13 Jul 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 133049250) .
Edit

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types (Incyte Corporation)

Public Technologies 13 Jul 2026
The data are being shared in an oral presentation today at the 34th Congress of the International Society on Thrombosis and Haemostasis (ISTH 2026 Congress) in Paris ... More information regarding the ISTH 2026 Congress can be found on the ISTH website.
Edit

Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress (Cadrenal Therapeutics Inc)

Public Technologies 13 Jul 2026
clinical trials and innovation in thrombosis, CAD-1005 took center stage before the global thrombosis community at the largest ISTH meeting in more than a decade ... (ISTH) 2026 Congress in Paris.
Edit

Novo Nordisk’s denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026 (Novo Nordisk A/S)

Public Technologies 11 Jul 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 133036961) .
Edit

Novo Nordisk's denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026

PR Newswire 11 Jul 2026
These results and other data across Novo Nordisk's hemophilia portfolio were presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Paris.
Edit

Gubra collaboration partner Hemab to present preclinical results for HMB-003, a potential treatment for multiple bleeding disorders, at the ISTH 2026 Congress (Gubra A/S)

Public Technologies 10 Jul 2026
2026-07-10 08.00.00 CEST Gubra A/S - Investor News Gubra collaboration partner Hemab to present preclinical results for HMB-003, a potential treatment for multiple bleeding disorders, at the ISTH 2026 Congress ... Presentations at the ISTH 2026 Congress.
Edit

Sobi to showcase new data across haemophilia portfolio at ISTH 2026 (Swedish Orphan Biovitrum AB)

Public Technologies 30 Jun 2026
) Sobi to showcase new data across haemophilia portfolio at ISTH 2026 ... the 2026 Congress of the International Society on Thrombosis and Haemostasis (ISTH), taking place in Paris, from 11-15 July 2026.
Edit

Sobi to showcase new data across haemophilia portfolio at ISTH 2026

PR Newswire 30 Jun 2026
"The breadth of data being presented at ISTH 2026 reflects our continued commitment to advancing care through both clinical development and real-world evidence generation to help improve outcomes for people living with haemophilia.".
Edit

Novo Nordisk to showcase new data across its hemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig

PR Newswire 26 Jun 2026
and BAGSVÆRD, Denmark, June 26, 2026 /PRNewswire/ -- Novo Nordisk today announced that new data will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Congress, July 11-15 in Paris, France.
Edit

Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH ...

Nasdaq Globe Newswire 24 Jun 2026
Selection highlights the clinical value potential of Cadrenal’s first-in-class 12-lipoxygenase inhibitor for Heparin-Induced Thrombocytopenia (HIT) ... .
Edit

Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress (Cadrenal Therapeutics Inc)

Public Technologies 24 Jun 2026
"The selection of our Phase 2 CAD-1005 study for a late-breakthrough oral presentation at ISTH is another milestone underscoring the scientific integrity and commercial importance of our pipeline," said Quang X.

Article Search

tools
×
×
×
×